Claudin 18.2-targeted CAR-T cells
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Claudin 18.2-targeted CAR-T cells, covering 2025-12-12 to 2025-12-12. Get the full timeline:
Most recent: Clinical Trial Update: Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma [Phase 1]